What is Nuclidium?
Nuclidium operates at the intersection of advanced chemistry and clinical oncology. The company is dedicated to the development of copper-based radiopharmaceuticals, a field that promises to redefine precision medicine. By leveraging a dual-isotope strategy, the firm provides a comprehensive solution for both the identification and treatment of malignant tumors. With operations spanning Switzerland and Germany, Nuclidium integrates deep scientific expertise with robust manufacturing capabilities, ensuring that its theranostic solutions are not only innovative but also scalable for global clinical application. The company's focus on overcoming existing radiotheranostic bottlenecks positions it as a high-growth entity within the life sciences sector, particularly as it targets unmet medical needs in complex oncology indications.
How much funding has Nuclidium raised?
Nuclidium has raised a total of $101.4M across 2 funding rounds:
Series A
$2.9M
Series B
$98.5M
Series A (2021): $2.9M, investors not publicly disclosed
Series B (2025): $98.5M led by Kurma Partners, Neva Sgr, Angelini Ventures, and Wellington Partners
Key Investors in Nuclidium
Kurma Partners
A prominent European firm specializing in healthcare innovation, Kurma Partners supports companies from pre-seed to growth stages with a focus on academic research and drug development.
Neva Sgr
Neva SGR is a venture capital firm that invests in high-potential startups across sectors including life sciences, focusing on empowering founders to address global challenges.
Angelini Ventures
Angelini Ventures focuses on transforming healthcare through technology, partnering with entrepreneurs to address unmet needs in vulnerable populations.
What's next for Nuclidium?
With the successful closure of this major enterprise-level funding, Nuclidium is well-positioned to advance its clinical-stage assets through critical regulatory and trial milestones. The strategic backing from specialized life science investors provides the necessary runway to expand manufacturing infrastructure and refine its copper-isotope platform. Moving forward, the company is expected to prioritize the acceleration of its lead candidates, potentially setting the stage for future partnerships or commercialization efforts. As the radiopharmaceutical market continues to attract significant venture interest, Nuclidium's ability to demonstrate clinical superiority will be the primary driver of its long-term valuation and market impact.
See full Nuclidium company page
